Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
growth - Attracts speculative biotech investors seeking asymmetric upside from clinical trial success and eventual royalty streams.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (royalties potentially 5-10+…
Watch on earnings: Phase 2 clinical trial data releases for ACI-35.030 and ACI-7104 (primary endpoints, safety profiles, biomarker responses), Quarterly collaboration revenue and guidance on upcoming milestone payment triggers, Cash burn rate and quarters of runway based on current operating expenses versus liquid assets.
One Sentence Summary:
AC Immune: the story is balanced — clinical trial data readouts for aci-35.030 phase 2 tau vaccine and aci-7104 anti-tau antibody programs.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.